HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

HUTCHMED

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Solid Tumor

Treatments: Drug: toripalimab; Drug: HMPL-453; Drug: Docetaxel; Drug: gemcitabine and cisplatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT05173142

2021-453-00CH1

Details and patient eligibility

About

This is a phase Ib/II clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of HMPL-453 combined with chemotherapy or anti-PD-1 antibody in patients with advanced solid tumors.

Full description

The study includes a dose escalation phase and a dose-expansion phase.

Patients with advanced solid tumor will be enrolled in the dose escalation phase to assess the tolerability, safety, and PK profile of HMPL-453 monotherapy or combination therapy.

Patients with specific types of advanced or metastatic tumors harboring certain FGFR gene alterations will be enrolled in the dose expansion phase to assess the preliminary efficacy of HMPL-453 combination therapy.

Enrollment: 141 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Dose escalation phase: patients with histologically or cytologically confirmed locally advanced or metastatic solid tumor who progressed on or are intolerant of standard therapy;
• Dose expansion phase: patients with UC, GC/GEJ, or IHCC harboring specific FGFR gene alterations;
• Age 18 to 75 years;
• Those who are able to give written informed consent, and able to comply with protocol-specified visits and related procedures;
• Ability to swallow study drug;
• ECOG PS of 0 or 1;
• Measurable lesion according to RECIST v1.1, refer to the protocol;
• Adequate organ and bone marrow function;
• Life expectancy ≥ 12 weeks;
• Female patients or male patients with partners of childbearing potential must take effective contraceptive measures per the protocol.

Exclusion Criteria

• Patients who previously received selective FGFR targeting therapy;
• Concurrent participation in another interventional clinical study, excluding those in the follow-up period and have not recently received investigational intervention;
• Current or previous history of central nervous system (CNS) metastases；
• Current or previous history of retinal detachment；
• Known history of primary immunodeficiency;
• Female patients who are pregnant or lactating；
• Patients who in the opinion of the investigator may be unsuitable for participating in the study;
• Patients with acute or chronic active hepatitis B or C infection;
• Known human immunodeficiency virus (HIV) infection and syphilis infection；
• Clinically significant cardiovascular disease such as congestive heart failure or arrhythmia；
• Uncontrolled hypertension despite optimal medical management；
• Received live vaccine within 30 days before the first dose of study drug(s);
• Those who have undergone major surgical procedures (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to the first study treatment or who are expected to be in need of major surgery; those with unhealed wounds, ulcers or fractures.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

141 participants in 2 patient groups

dose escalation phase of HMPL-453 monotherapy or combination therapy

Experimental group

Description:

HMPL-453 monotherapy or combination therapy

Treatment:

Drug: toripalimab

Drug: HMPL-453

Drug: gemcitabine and cisplatin

indication specific dose expansion phase of HMPL-453 combination therapy

Experimental group

Description:

HMPL-453 combined with chemotherapy or anti-PD-1 antibody, in patients with IHCC, G/GEJ, or UC harboring specific FGFR gene alterations

Treatment:

Drug: toripalimab

Drug: HMPL-453

Drug: Docetaxel

Drug: gemcitabine and cisplatin